Veracyte (VCYT) to Acquire Decipher Biosciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 subdued as gains in banks offset AI jitters; Dow at one-month high
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Stocks edge lower as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
Veracyte (VCYT) Prices 7.43M Share Upsized Common Offering at $74/Sh
February 5, 2021 6:09 AM ESTVeracyte, Inc. (NASDAQ: VCYT) (the Company) today announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74.00 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be approximately $550 million. The public offering was upsized from the previously... More



